Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SGLT2 Inhibition (Dapagliflozin) in Diabetic and Non-diabetic Hemodialysis Patients With and Without Residual Urine Volume: a Prospective Randomized, Placebo-controlled, Double-blinded Phase II Trial

NCT05179668 is registered in ClinicalTrials.gov with Medical University of Vienna as lead sponsor.

NCT NCT05179668
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05179668 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SGLT2 Inhibition (Dapagliflozin) in Diabetic and Non-diabetic Hemodialysis Patients With and Without Residual Urine Volume: a Prospective Randomized, Placebo-controlled, Double-blinded Phase II Trial
Lead sponsor
Medical University of Vienna
Phase
Phase 2
Overall status
Completed
Start date
October 1, 2022
Completion date
February 28, 2026
Enrollment
220 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease, diabetes mellitus, type 2, hemodialysis, kidney failure, left ventricular hypertrophy